The gemtuzumab ozogamicin and historical control groups were similar with respect to demographic characteristics ( Table 1). The average age among the gemtuzumab ozogamicin-treated patients was 57 ...
The outcomes of treatment with gemtuzumab ozogamicin compared with those of conventional chemotherapy for relapse of acute myelogenous leukemia (AML) were studied. The gemtuzumab ozogamicin group ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback